Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2016-01-12Clinical Trial Update: Development of Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads
A Yale University-sponsored clinical trial studying a sleep intervention for people with Alzheimer's disease and their caregivers has been w…
-
CLINICAL_TRIALS withdrawal · 2015-10-26Clinical Trial Update: Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) [Phase 4]
This Phase 4 clinical trial comparing Cerebrolysin to Donepezil in patients with mild to moderate Alzheimer's disease was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-10-15Clinical Trial Update: Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine [Phase 2]
Phase 2 study evaluating the safety of two doses of EVP-6124 in people with Alzheimer's disease who are receiving memantine has been withdra…
-
CLINICAL_TRIALS withdrawal · 2015-08-24Clinical Trial Update: Pilot Study of the Effects of Resveratrol Supplement in Mild-to-moderate Alzheimer's Disease [Phase 3]
This document reports the withdrawal of a Phase 3 pilot trial evaluating resveratrol supplementation in patients with Alzheimer's disease.
-
CLINICAL_TRIALS withdrawal · 2015-06-26Clinical Trial Update: Reminiscence, Anxiety and Early Alzheimer's Disease [NA]
Clinical trial investigating reminiscence and anxiety in early Alzheimer's disease has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-05-27Clinical Trial Update: Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients [Phase 4]
This report indicates that the Phase 4 trial evaluating safety and efficacy of divalproex in combination with quetiapine for elderly patient…
-
CLINICAL_TRIALS withdrawal · 2015-04-17Clinical Trial Update: QTc Study of Rosi XR in Healthy Volunteers [Phase 1]
A Phase 1 QTc study of the drug Rosi XR in healthy volunteers has been withdrawn by the sponsor, GlaxoSmithKline.
-
CLINICAL_TRIALS withdrawal · 2015-03-10Clinical Trial Update: Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Alzheimer's Disease
The clinical trial comparing cellular proteomes from leukocytes of glaucoma patients with those of Alzheimer's disease patients has been wit…
-
CLINICAL_TRIALS withdrawal · 2015-02-10Clinical Trial Update: Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment [Phase 2]
Phase 2 trial evaluating multiple-dose regimens of CHF 5074 in subjects with mild cognitive impairment and potential progression to Alzheime…
-
CLINICAL_TRIALS withdrawal · 2014-10-23Clinical Trial Update: Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians [NA]
A clinical trial evaluating electronic interpretation training for Florbetapir F-18 PET imaging in Japanese physicians was withdrawn.
-
EMA withdrawal · 2014-09-18EMA Withdrawn: Rivastigmine 3M Health Care Ltd (rivastigmine) — 3M Health Care Limited
EMA withdrew the rivastigmine product from 3M Health Care Limited, with the withdrawn status recorded for Alzheimer disease treatment.
-
CLINICAL_TRIALS withdrawal · 2014-03-13Clinical Trial Update: Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease [NA]
The trial investigating pulsatile intravenous insulin for Alzheimer's disease and mild cognitive impairment has been withdrawn.
-
EMA withdrawal · 2013-04-10EMA Application withdrawn: Memantine FGK (memantine) — FGK Representative Service GmbH
The EMA application for Memantine FGK (memantine) has been withdrawn by FGK Representative Service GmbH.
-
EMA withdrawal · 2013-03-11EMA Refused: Acrescent (memantine hydrochloride;donepezil hydrochloride) — H. Lundbeck A/S
EMA refused the Acrescent (memantine hydrochloride; donepezil hydrochloride) application for Alzheimer’s disease.
-
CLINICAL_TRIALS withdrawal · 2012-12-10Clinical Trial Update: Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease [Phase 4]
The Phase 4 trial evaluating donepezil for behavioral and psychological symptoms in severe Alzheimer's disease was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-12-04Clinical Trial Update: AC-1204 Long-term Efficacy Response Trial (ALERT Protocol) [Phase 2, Phase 3]
Cerecin has withdrawn the long-term efficacy ALERT trial (AC-1204) in Alzheimer's disease after Phase 2/3.
-
CLINICAL_TRIALS withdrawal · 2012-11-14Clinical Trial Update: Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease [NA]
The clinical trial NCT00412048 evaluating functional MRI-SAM in Alzheimer's disease has been withdrawn.
-
EMA withdrawal · 2012-09-27EMA Withdrawn: Rivastigmine Teva (rivastigmine) — Teva Pharma B.V.
The EMA withdrew Rivastigmine Teva (rivastigmine) from its European market authorization.
-
CLINICAL_TRIALS withdrawal · 2011-05-30Clinical Trial Update: Study of Magnetic Fields to Treat Alzheimer's Disease [NA]
A clinical trial evaluating pico-tesla magnetic field therapy for Alzheimer's disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2010-06-29Clinical Trial Update: A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease [Phase 2]
Pfizer's Phase 2 study of the investigational drug PF-01913539 in mild-to-moderate Alzheimer's disease has been withdrawn.